contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-eqts-value-creation-day-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

EQT is a venture capital firm. The company operates in the investment industry and focuses on private equity and infrastructure investments. The company's portfolio includes companies in sectors such as technology, healthcare and industrials. The business is global with a primary presence in Europe, North America and Asia. EQT was founded in 1994 and is headquartered in Stockholm, Sweden.

EQT is selling a 30 percent minority stake in Nordic Ferry Infrastructure to a group, but remains the company’s main owner. NFI has grown into a major ferry operator in the Nordics, transporting over 25 million passengers annually. With new owners, the company aims to further develop its operations, expand judiciously, and invest in low-emission and electric vessels. No sums were mentioned in the release.     A consortium of Rederiaktiebolaget Gotland AB, publ., Interogo Infrastructure and Lægernes Pension to acquire a 30 percent minority stake in Nordic Ferry Infrastructure   Nordic Ferry Infrastructure operates essential ferry infrastructure across the Nordics, serving more than 25 million passengers annually across a network of over 1,400 km   The broadened investor base adds resources to support the next phase of Nordic Ferry Infrastructure’s development, including future fleet decarbonization and electrification investments, selective growth, and further operational development across the platform                      Inderes              EQT broadens investor base in Nordic Ferry Infrastructure following...    A consortium of Rederiaktiebolaget Gotland AB, publ., Interogo Infrastructure and Lægernes Pension to acquire a 30 percent minority stake in Nordic Ferry Infrastructure Nordic Ferry Infrastructure...

Today, EQT released a PRESS release stating that EQT Life Sciences is selling its minority stake in the German biotechnology company Tubulis to Gilead Sciences. The deal could be worth up to $5 billion, with $3.15 billion paid immediately in cash. Tubulis develops new cancer drugs, and EQT helped it grow and develop. Going forward, Tubulis will operate as part of Gilead and continue its research internationally.  Press Release EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion  Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company EQT Life Sciences led the Series B2 financing of Tubulis in March 2024, and has since supported the Company at board level in its growth to a leading global clinical-stage ADC company  EQT Life Sciences is pleased to announce that the LSP 7 fund (“EQT Life Sciences”) has exited its minority stake in Tubulis (the “Company”), a Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), through a sale to Gilead Sciences [Nasdaq: GILD].  Tubulis’ lead asset, TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Gilead will also acquire TUB-030, a 5T4 targeted ADC, which has demonstrated promising initial clinical data across various solid tumor types as well as a next-generation ADC platform and a promising early pipeline. EQT Life Sciences co-led the oversubscribed Series B2 financing in 2024, and since then, has helped Tubulis advance into a clinical-stage oncology player, progress its pipeline, and build a differentiated antibody-drug conjugate platform targeting solid tumors. Working closely with the management team, EQT Life Sciences supported this journey through active board involvement and strategic guidance, helping position Tubulis as a partner of choice in a rapidly growing and highly competitive field. The transaction represents a strong and strategic outcome for LSP 7 and its co-investors, and reflects EQT Life Sciences’ ambition to back outstanding science early, helping companies scale through critical inflection points into globally relevant businesses. Today’s announcement also underscores the continued demand for innovative oncology platforms that can address significant unmet medical needs. “From the outset, we believed our conjugation technology platforms could have broad impact across the ADC field, and the initial data from TUB-040 have reinforced that conviction,” said Dominik Schumacher, PhD, Chief Executive Officer and Co-founder of Tubulis. “Joining Gilead allows us to build on this foundation within an organization that brings deep scientific expertise, global development capabilities, and the scale needed to translate innovation into medicines for patients worldwide. Through our existing collaboration, Gilead has already seen the potential of our technologies and together, we are well positioned to accelerate the development of our ADC pipeline. I’m deeply grateful to the Tubulis team, our Board of Directors, investors, and partners for their commitment and helping make this milestone possible.” “From day one, it was clear that Tubulis had both the science and the ambition to compete at the very highest level in oncology,” said Christoph Broja, Partner at EQT Life Sciences and Board Director at Tubulis." A European-born platform with world-class talent and technology, this is exactly the kind of company EQT Life Sciences was built to back. Today’s announcement is a testament to that conviction, and we are proud to have supported its journey from Munich to the global stage" Following the close of the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, building on its integrated discovery, manufacturing, and clinical capabilities to advance next generation ADCs. Terms of the Transaction Under the terms of the sale and purchase agreement, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration on a cash-free, debt-free basis, subject to customary adjustments, which is payable at closing, and up to $1.85 billion in contingent milestone payments. Closing of the transaction is subject to expiration or termination of certain regulatory filings and other customary conditions. The transaction is expected to close in the second quarter of 2026. Gilead plans to finance the transaction with a combination of cash on hand and senior unsecured notes. Centerview Partners LLC and Allen & Company LLC are acting as financial advisors for Gilead. J.P. Morgan Securities LLC is acting as the exclusive financial advisor for Tubulis. Covington & Burling LLP, Arnold & Porter LLP, and Venable LLP are serving as legal counsel to Gilead. Goodwin Procter LLP and CMS Hasche Sigle are serving as legal counsel to Tubulis.                    Inderes              EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead...    Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company EQT Life Sciences led the Series B2 financing of Tubulis...

EQT and Atomico appear to be the last two companies on the shortlist to manage the €5 billion Scaleup Europe Fund. Three other shortlisted companies—Eurazeo, Northzone, and Vitruvian Partners—were informed on Wednesday that they would not be moving forward. The Scaleup Europe Fund invests in strategic sectors such as space technology, artificial intelligence, quantum, and biotechnology, and it is the largest fund of its kind in the region.                   LinkedIn              LinkedIn: Kirjaudu sisään tai rekisteröidy    1 miljardia jäsentä | Hallitse ammattilaisidentiteettiäsi. Rakenna ammattilaisverkostoasi ja osallistu sen toimintaan. Käytä hyväksesi tietoa, oivalluksia ja mahdollisuuksia.

EQT has sold a large logistics portfolio of 36 properties in the US to Ares. The transaction covers approximately 680,000 square meters of modern warehouse space in prime locations. The sale is a continuation of previous actions and indicates that investors are still interested in well-maintained and strategically located industrial properties with growth potential.   Transaction represents the second tranche of a significant disposition from EQT Real Estate’s Core-Plus industrial portfolio Portfolio comprised of 36 logistics assets totalling approximately 7.3 million square feet Sale demonstrates continued investor appetite for scaled, stabilized, and well-located logistics assets with embedded growth potential                     Inderes              EQT Real Estate announces sale of 7 million square foot logistics portfolio...    Transaction represents the second tranche of a significant disposition from EQT Real Estate's Core-Plus industrial portfolio Portfolio comprised of 36 logistics assets totalling approximately...

Investor continues to snap up shares. https://www.marketscreener.com/news/major-shareholder-investor-buys-eqt-shares-for-sek-152-million-ce7e5ed8de89fe2c 543,733 shares in the private equity firm EQT between March 16 and 17. The shares were acquired at an average price of SEK 279.31 per share

Chairman of the Board shopping for 76 million kronor. https://www.marketscreener.com/news/eqt-s-proposed-new-chairman-salata-purchases-shares-for-sek-76-million-ce7e5ed8de89f426

https://www.marketscreener.com/news/rausing-on-eqt-stake-we-have-great-confidence-efn-ce7e5fd2d089f726 The wealthy Swedish Rausing family disclosed exceeding a 5% stake in EQT. They have been involved since the IPO.

For the second consecutive year, EQT is pleased to invite you to its 2026 "Value Creation Day" on 20 May in London. The event will be hosted by EQT's CEO & Managing Partner, Per Franzén, and...

<div class="abstract">For the second consecutive year, EQT is pleased to invite you to its 2026 "Value Creation Day" on 20 May in London. The event will be hosted by EQT's CEO &amp; Managing Partner, Per Franzén, and will feature insights from EQT's investment advisory professionals, digital &amp; AI teams, and portfolio company CEOs.</div>The program will offer a cross-portfolio perspective on EQT's value creation approach, highlighting how EQT invests behind the AI opportunity and actively leverages AI to drive operational performance, unlock new growth opportunities and create long-term value across the portfolio.Since its founding in 1994, EQT has been investing behind the technological shifts that define each generation. Today, EQT is uniquely positioned to capture the AI opportunity at scale. EQT invests across the full company lifecycle from early-stage AI natives to mature businesses, and backs companies at the core of the AI ecosystem across its global platform, from data centres and energy infrastructure to companies across sectors with strong AI-driven transformation potential. With an industrial approach to value creation, EQT combines an active ownership model with deep operational expertise to drive ambitious AI-enabled value creation across its portfolio.At the 2026 edition of the event, EQT's Infrastructure and Private Capital teams will present their AI investment theses, covering the spectrum of opportunities from native AI companies to the data centres and energy infrastructure underpinning the AI buildout. Representatives from EQT's in-house digital and AI teams will also share how AI tools and capabilities are embedded across the portfolio as part of EQT's repeatable value creation framework.&nbsp;The event will also feature presentations from the CEOs of Anticimex, CFC, EdgeConneX and Straive, who will share their strategic priorities, operational progress and long-term ambitions.&nbsp;If you are interested in meeting one-on-one with the participating portfolio companies as an institutional investor, please contact <a href="mailto:shareholderrelations@eqtpartners.com">shareholderrelations@eqtpartners.com</a>. The event will be hosted in person at The Ned in the City of London. Registration and lunch will commence at 12:00 BST, followed by an afternoon of panel discussions and Q&amp;A sessions with EQT leaders and portfolio company CEOs.Attendance is intended for institutional investors, analysts, financial advisors, distribution partners, and media representatives. Please register <a href="https://eqtvaluecreationday2026.splashthat.eu/">here</a> to attend.We look forward to welcoming you!ContactOlof Svensson, Head of Shareholder Relations, +46 72 989 09 15 EQT Press Office, press@eqtpartners.com, +46 8 506 55&nbsp;334<div></div>